Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Phase 1

Completed

• Conditions: Malignant Melanoma
• Interventions: Drug: Ipilimumab; Biological: UV1 vaccine; Biological: GM-CSF

• Registration Number: NCT02275416
• Lead Sponsor: Ultimovacs ASA

Brief Summary

This study, with 20 patients participating, will examine the safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma.

Detailed Description

This is a phase I/IIa, national, open label, single arm, interventional study examining safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma. Patients that have signed the informed consent form will be asked to take part in the study. All patients will receive ipilimumab together with the UV1 vaccine and rranulocyte-macrophage colony-stimulating factor (GM-CSF). Ipilimumab will be given every 3rd week for a total of 4 doses. The UV1 vaccine and GM-CSF will be given before and between treatments of ipilimumab. The maximum number of UV1/GM-CSF will be 10 doses.

Immunoresponders maybe followed up every third months for 5 years after the first UV1 treatment. Follow-up is onging.

Study Timeline

• Study First Submitted: 2014-09-12
• Study First Submitted QC: 2014-10-24
• Study First Posted: 2014-10-27
• Study Start: 2015-02-02
• Primary Completion: 2016-10-06
• Study Completion: 2020-11-03
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-11
• Last Update Posted: 2024-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Histologically or cytologically confirmed diagnosis of unresectable or metastatic malignant melanoma, including cutaneous, ocular, mucosal and unknown primary tumour.

2. Unresectable Stage III or Stage IV melanoma (AJCC 2010)

3. Prior adjuvant melanoma therapy is permitted; any number of previous treatments for melanoma is permitted.

4. ECOG performance status of 0 or 1 (see Error! Reference source not found.).

5. Men and women ≥ 18 years of age

6. Adequate hematologic, renal and hepatic function, specifically:

   1. WBC ≥ 2500/μL
   2. Absolute neutrophil count (ANC) ≥ 1000/uL
   3. Platelets ≥ 75 x 103/μL
   4. Haemoglobin ≥ 9 g/dL
   5. Creatinine ≤ 2.5 x ULN
   6. AST/ALT ≤ 3 x ULN for patients without liver metastasis; ≤ 5 x ULN for patients with liver metastasis
   7. Total bilirubin ≤ 3 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)

7. Women of childbearing potential and men must be using an acceptable method as described in the protocol to prevent pregnancy.

8. Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.

Exclusion Criteria

1. History of or current active autoimmune diseases, including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (e.g. Guillain-Barre syndrome). Patients with vitiligo are not excluded.
2. MRI detected active brain metastasis witch require other therapies such as surgery and/or radiation therapy. Patients already treated for their brain metastasis, surgery or radiation therapy, and have had stable disease for more than two month and NOT requiring steroids may however be included in this study.
3. Uncontrolled infectious diseases - requires negative tests for clinically suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV).
4. History of or current immunodeficiency disease, splenectomy or splenic irradiation
5. Prior allogeneic stem cell transplantation
6. Pregnancy
7. Women who are breastfeeding
8. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of Adverse Events, such as a condition associated with frequent diarrhoea
9. History of allergic reaction to parenteral administered recombinant protein product
10. History of another malignancy that in the opinion of the investigator may compromise the outcome of the study
11. Any reason why, in the opinion of the investigator, the patient should not participate.
12. Known serious reactions or hypersensitivity to any components of the UV1 vaccine or similar peptide based vaccines
13. Known hypersensitivity to GM-CSF
14. Known hypersensitivity to any of the excipients of the investigational products
15. Concomitant use of antithrombotic agents with the exception of platelet inhibitors.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ipilimumab & UV1 vaccine & GM-CSF	UV1 vaccine	Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
Ipilimumab & UV1 vaccine & GM-CSF	GM-CSF	Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
Ipilimumab & UV1 vaccine & GM-CSF	Ipilimumab	Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.

Primary Outcome Measures

Name	Time	Method
Safety and tolerability profile. Frequency/ severity of adverse and serious adverse events. Biochemistry and hematology results, vital signs and ECOG	Up to 53 weeks	Frequency and severity of adverse events and serious adverse events. Biochemistry and hematology results, vital signs and ECOG performance status will be assessed.

Secondary Outcome Measures

Name	Time	Method
Health Related Quality of Life (HRQL)	Up to 53 weeks	HRQL measured by use of patient questionnaire EORTC QLQ-C30
Immunological response. Number of T-cell responses including time to T-cell response, level of response and duration of response.	Up to 53 weeks	Number of T-cell responses including time to T-cell response, level of response and duration of response.
Treatment response. Tumour response evaluated by CT scan every 12th week.	Up to 48 weeks	Tumour response evaluated by CT scan every 12th week.

Trial Locations

Locations (1)

Oslo University Hospital, Radiumhospitalet; 🇳🇴 Oslo, Norway